| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -7.2 | -8.9 |
| EPS (diluted, $ a share) | $-0.12 | $-0.27 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: MAIA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Maia Biotechnology, Inc.: key numbers
- Share price
- $1.25Close, Nov 17
- Market cap
- $77.2M
- Shares outstanding
- 61.75MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Maia Biotechnology, Inc.
All →Maia Biotechnology Insider Stan Smith Buys $100K of Stock
Stan Smith bought 100,000 shares of Maia Biotechnology, Inc. at $1.00 a share, worth $100K in total between Nov 13, 2026 and Nov 16, 2026. Shares held after the trade: 1,619,178 (+1.2%).
- Value
- $100K
- Shares
- 100,000
- Average price
- $1.00
- Holding change
- +1.2%
- Trade date
- Nov 13, 2026 to Nov 16, 2026
Maia Biotechnology CEO Vlad Vitoc Buys $100K of Stock
Vlad Vitoc, CEO, bought 100,000 shares of Maia Biotechnology, Inc. at $1.00 a share, worth $100K in total between Nov 13, 2026 and Nov 16, 2026. Shares held after the trade: 1,149,121 (+3.6%).
- Value
- $100K
- Shares
- 100,000
- Average price
- $1.00
- Role
- CEO
- Holding change
- +3.6%
- Trade date
- Nov 13, 2026 to Nov 16, 2026
Maia Biotechnology Clinical Trial Data
MAIA Biotechnology reported updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating ateganosine (THIO) in patients with advanced non-small cell lung cancer (NSCLC). The trial demonstrated an 88% disease control rate (DCR) in third-line patients who had progressed after prior immunotherapy and chemotherapy, significantly higher than the 25-35% DCR typically seen with standard chemotherapy.
Maia Biotechnology Investor Presentation
MAIA Biotechnology, Inc. has prepared and posted a new corporate investor presentation and a summary highlighting its operations and performance to its website. Management intends to use these materials for upcoming presentations to investors and analysts starting October 6, 2026.
Maia Biotechnology Insider Ramiro Guerrero Buys $49.5K of Stock
Ramiro Guerrero bought 37,595 shares of Maia Biotechnology, Inc. at $1.32 a share, worth $49.5K in total on Sep 10, 2026. Shares held after the trade: 773,296 (+5.1%).
- Value
- $49.5K
- Shares
- 37,595
- Price
- $1.32
- Holding change
- +5.1%
- Trade date
- Sep 10, 2026